Status:
UNKNOWN
Do Markers of Systemic Inflammatory Response and Tumor Metabolism Indicate Radioresistance in Head and Neck Cancer?
Lead Sponsor:
Luzerner Kantonsspital
Collaborating Sponsors:
Universität Luzern
Conditions:
Head and Neck Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to prospectively evaluate whether markers of a patient's systemic inflammatory response in addition to FDG-PET/CT metabolic parameters of the primary tumor or of nodal metastas...
Detailed Description
This study prospectively investigates pretherapeutic markers of systemic inflammatory response (including neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, sy...
Eligibility Criteria
Inclusion
- histopathologic diagnosis of squamous cell carcinoma of the head and neck
- primary radio(chemo)therapy with curative intent
- available pretherapeutic FDG-PET/CT imaging
- available pretherapeutic differential blood analysis
Exclusion
- other tumor entities of the head and neck including cutaneous squamous cell carcinoma
- primary surgical treatment
- ongoing infections or other inflammatory diseases at the time of diagnosis
- patients not completing a course of irradiation with at least 66 Gray locally
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05217212
Start Date
January 1 2020
End Date
December 1 2025
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Otorhinolaryngology - Head and Neck Surgery, Cantonal Hospital Lucerne
Lucerne, Switzerland